Q-Line Biotech
QLINE NSE
Q-Line Biotech
HealthcareNSE: QLINE Medical Equipment
Key Fundamentals
SMEMedical EquipmentHealthcareMarket Cap
₹1,670 Cr
Volatility
High Risk
P/E Ratio
29.9
EBITDA
₹97.06 Cr
Return on Equity
12.91%
Debt to Equity
0.91
Book Value
₹209.24
52W High
₹720
52W Low
₹343
Tapetide Score
Data-driven rating, 0–100. How it works →
Key Insights
Strengths
1- Company has a good return on equity (ROE) track record: 3 Years ROE 25.2%
Weaknesses
1- Debtor days have increased from 92.7 to 134 days.
Growth Rate
Revenue Growth
5.93% lower than
3Y
Net Income Growth
127% higher than
3Y
ROE
-3.44% lower than
3Y
ROCE
15% higher than
3Y
EBITDA Margin (Avg.)
8.34% lower than
3Y
Quarterly Results
| Particulars | Mar 2025 | Mar 2026 |
|---|---|---|
| Sales | 217 | 198 |
| Expenses | 172 | 136 |
| Operating Profit | 45 | 62 |
| OPM % | 21% | 31% |
| Other Income | -11 | 2 |
| Interest | 8 | 11 |
| Depreciation | 3 | 7 |
| PBT | 22 | 46 |
| Tax % | 71% | 26% |
| Net Profit | 9 | 34 |
| EPS in Rs | 56.13 | 21.14 |
Profit & Loss
| Particulars | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| Sales | 183 | 203 | 314 | 342 |
| Expenses | 149 | 165 | 239 | 244 |
| Operating Profit | 34 | 38 | 75 | 98 |
| OPM % | 18% | 19% | 24% | 29% |
| Other Income | 2 | 3 | -8 | 5 |
| Interest | 4 | 6 | 15 | 19 |
| Depreciation | 2 | 4 | 7 | 11 |
| PBT | 30 | 31 | 44 | 73 |
| Tax % | 28% | 29% | 45% | 23% |
| Net Profit | 32 | 34 | 28 | 56 |
| EPS in Rs | 204 | 219 | 179 | 34.24 |
| Div. Payout % | 0% | 0% | 0% | 0% |
Balance Sheet
| Particulars | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| Equity Capital | 2 | 2 | 2 | 16 |
| Reserves | 126 | 160 | 188 | 230 |
| Borrowings | 74 | 97 | 166 | 225 |
| Other Liabilities | 51 | 81 | 99 | 87 |
| Total Liabilities | 252 | 339 | 455 | 559 |
| Fixed Assets | 23 | 60 | 92 | 145 |
| CWIP | 12 | 19 | 63 | 15 |
| Investments | 16 | 29 | 0 | 17 |
| Other Assets | 201 | 232 | 301 | 381 |
| Total Assets | 252 | 339 | 455 | 559 |
Cash Flow
| Particulars | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| Operating | 25 | -24 | -1 | 16 |
| Investing | -26 | -45 | -59 | -29 |
| Financing | 26 | 17 | 53 | 42 |
| Net Cash Flow | 25 | -52 | -7 | 29 |
| Free Cash Flow | -5 | -72 | -58 | -19 |
| CFO/OP | 111 | -39 | 7 | 43 |
Ratios
| Particulars | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| Debtor Days | 66 | 47 | 96 | 134 |
| Inventory Days | 180 | 413 | 226 | 258 |
| Days Payable | 164 | 232 | 139 | 142 |
| Cash Conversion Cycle | 82 | 228 | 183 | 251 |
| Working Capital Days | -44 | 51 | 45 | 62 |
| ROCE % | — | 16% | 25% | 22% |
Insights
BetaAI-extracted from concalls & annual reports · figures as reported, with sources
Log in to view Q-Line Biotech insights
36 extracted metrics + investor summaries across FY23–FY26.
Documents
1
Updates
11 Sep - Sent AGM annual report links; AGM on 30 Sept 2026, remote voting 27-29 Sept, KYC reminder. 11 Sep - Sent AGM annual report links; AGM on 30 Sept 2026, remote voting 27-29 Sept, KYC reminder.
2
Copy of Newspaper Publication
8 Sep - Newspaper notice published for 16th AGM on September 30, 2026, at Lucknow venue in physical mode. 8 Sep - Newspaper notice published for 16th AGM on September 30, 2026, at Lucknow venue in physical mode.
3
Updates
8 Sep - Q-Line Biotech corrects AGM number typo: 37th to 16th in September 7 intimation subjects. 8 Sep - Q-Line Biotech corrects AGM number typo: 37th to 16th in September 7 intimation subjects.
4
Updates
7 Sep - Q-Line Biotech filed FY2025-26 annual report and AGM notice for 30 September 2026. 7 Sep - Q-Line Biotech filed FY2025-26 annual report and AGM notice for 30 September 2026.
5
General Updates
7 Sep - Q-Line Biotech submitted FY2025-26 annual report and scheduled AGM on 30 September 2026. 7 Sep - Q-Line Biotech submitted FY2025-26 annual report and scheduled AGM on 30 September 2026.
Frequently Asked Questions about Q-Line Biotech
What does Q-Line Biotech Ltd do?
Incorporated in 2010, Q-Line Biotech Ltd.
is engaged in the business of developing, manufacturing and marketing a diverse
range of reagents.[1]
Where is Q-Line Biotech Ltd (QLINE) listed?
Q-Line Biotech Ltd trades as QLINE on the NSE.
Which sector does Q-Line Biotech Ltd belong to?
Q-Line Biotech Ltd is classified under the Healthcare sector, in the Medical Equipment industry.
What is the market capitalisation of Q-Line Biotech Ltd?
Q-Line Biotech Ltd has a market capitalisation of ₹1,670 Cr, which places it in the Small Cap band.
What is the PE ratio of Q-Line Biotech Ltd?
Q-Line Biotech Ltd trades at a PE ratio of 29.90, against a book value of ₹209.24 per share.
What is the 52-week high and low of Q-Line Biotech Ltd?
Over the last 52 weeks Q-Line Biotech Ltd has traded between ₹343 and ₹720.
What is the Return on Equity (ROE) of Q-Line Biotech Ltd?
Q-Line Biotech Ltd reported a return on equity of 12.91%. Its debt-to-equity ratio is 0.91.
Company Information
Incorporated in 2010, Q-Line Biotech Ltd. is engaged in the business of developing, manufacturing and marketing a diverse range of reagents.[1]
For AI agents and developers
Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/QLINE.md for Q-Line Biotech Ltd: company profile, latest price, key fundamentals, the Tapetide Score, growth rates, quarterly and annual financial statements, shareholding pattern, technical indicators, analyst ratings and exchange filings.
Append .md to any Tapetide URL for the
same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live,
structured queries instead of documents, use our MCP server.